While IFN‐β is an established therapy in relapsing MS and the interferon‐alpha/beta receptor (IFNAR) signaling on myeloid cells limits autoimmunity in the CNS [4], IFN‐α drives pathogenesis in SLE. This evidence concerns the gene IFNA1 and systemic lupus erythematosus.